Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.54 |
| ▸ | CTSK | P43235 | 8/20 | 0.54 |
| ▸ | CTSB | P07858 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057468 | 1.00 | CTSS (0.54) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL571948 | 0.92 | REN (0.53) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL10057469 | 0.92 | REN (0.53) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL572951 | 0.87 | CTSS (0.53) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL342708 | 0.85 | DPP4 (0.43) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL28759095 | 0.85 | DPP4 (0.43) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL29364846 | 0.85 | DPP4 (0.43) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL342707 | 0.85 | DPP4 (0.43) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL10057576 | 0.83 | CTSS (0.41) | CTSSCTSKRENKLK5PTPN1 | |
| SCHEMBL571933 | 0.83 | CTSS (0.41) | CTSSCTSKRENKLK5PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600888-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Pharmaceuticals Ltd. (IN) | 2013-06-12 | — | — | EP | disclosed |
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | DPP4, DPP7, DPP3 | CTSS 443/4885CTSK 379/4885CTSB 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.